Better medicines for children: What has been achieved by the EU Paediatric Regulation after 5 years?;Bessere Arzneimittel für Kinder: Wie viel hat die "paediatric Regulation" der EU nach 5 Jahren erreicht?

Monatsschrift fur Kinderheilkunde

Volumn 161, Issue 4, 2013, Pages 301-307

  Male, C ^a  

^a UNIV KLIN KINDER JUGENDHEILKUNDE   (Austria)

Author keywords

Authorization; Children; Clinical trial; Drugs; Pediatric regulation

Indexed keywords

ARTICLE; CHILD HEALTH CARE; DRUG APPROVAL; DRUG DESIGN; DRUG INDICATION; DRUG INDUSTRY; PHARMACEUTICAL CARE; RISK BENEFIT ANALYSIS;

EID: 84879902759     PISSN: 00269298     EISSN: 14330474     Source Type: Journal    
DOI: 10.1007/s00112-012-2791-5     Document Type: Article

References (25)

1. Conroy S, McIntyre J, Choonara I (1999) Unlicensed and off label drug use in the neonate. Arch Dis Child Fetal Neonatal Ed 80:F142-F145
2. European Commission (2012) FP7 cooperation work programme: health 2013. European Commission, Brüssel. ftp://ftp.cordis.europa.eu/pub/fp7/health/ docs/fp7-health-wp-2013-en.pdf. Zugegriffen: 15.01.2013
3. European Commission (2012) General report on experience acquired as a result of the application of the Paediatric Regulation (no 1901/2006), 'experience acquired' and 'lessons learnt' submitted for public consultation. European Commission, Brüssel. http://ec.europa.eu/health/files/paediatrics/ 2012-09-publicconsultation-en.pdf. Zugegriffen: 15.01.2013
4. European Medicines Agency (2007) Inventory of paediatric needs. EMA, London. http://www.emea.europa.eu/htms/human/paediatrics/inventory.htm. Zugegriffen: 15.01.2013
5. European Medicines Agency (2010) Report on the survey of all paediatric uses of medicinal products in Europe, executive summary, EMA/761434/2010. EMA, London. http://www.ema.europa.eu/docs/en-GB/document-library/Other/2011/01/ WC500101008.pdf. Zugegriffen: 15.01.2013
6. European Medicines Agency (2011) EU clinical trials register. EMA, London. https://www.clinicaltrialsregister.eu/index.htm. Zugegriffen: 15.01.2013
7. European Medicines Agency (2011) Mission statement of the European network of paediatric research at the European Medicines Agency (Enpr-EMA). EMA, London. http://www.ema.europa.eu/docs/en-GB/document-library/Other/2012/02/ WC500123158.pdf. Zugegriffen: 15.01.2013
8. European Medicines Agency (2012) 5-year report to the European Commission: general report on the experience acquired as a result of the application of the paediatric regulation. EMA, London. http://ec. europa.eu/health/files/paediatrics/2012-09- pediatric-report-annex1-2-en.pdf. Zugegriffen: 15.01.2013
9. European Medicines Agency (2012) Paediatric workshops. EMA, London. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/general/ general-content-000416.jsp&mid=WC0b01ac0580118a19. Zugegriffen: 15.01.2013
10. European Medicines Agency (2012) PDCO monthly report, December 2012. EMA, London. http://www.emea.europa.eu/docs/en-GB/document-library/Committee- meeting-report/2012/12/WC500136450.pdf. Zugegriffen: 15.01.2013
11. European Medicines Agency (2013) Opinions on paediatric investigation plans. EMA, London. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/ landing/pip-search.jsp&mid=WC0b01ac058001d129. Zugegriffen: 15.01.2013
12. European Medicines Agency (2013) Paediatric studies submitted in accordance with Article 45 of the paediatric regulation. EMA, London. http://art45-paediatric-studies.ema.europa.eu/clinicaltrials/. Zugegriffen: 15.01.2013
13. European Medicines Agency (2013) Revised priority list for studies into off-patent paediatric medicinal products. EMA, London. http://www.ema.europa.eu/ docs/en-GB/document-library/Other/2009/10/WC500004017.pdf. Zugegriffen: 15.01.2013
14. European Parliament and Council (2006) Regulation (EC) No 1901/2006 and 1902/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use. Paediatric regulation. Official J Eur Union 18:L378/1
15. Horen B, Montastruc J, Lapeyre-Mestre M (2002) Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Pharmacol 54:665-670
16. Johnson TN (2005) Modelling approaches to dose estimation in children. Br J Clin Pharmacol 59(6):663-669
17. Kearns GL, Abdel-Rahman SM, Alander SW et al (2003) Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157-1167
18. Lindell-Osuagwu L, Korhonen MJ, Saano S et al (2009) Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 34:277-287
19. Mukattash T, Hawwa AF, Trew K, McElnay JC (2011) Healthcare professional experiences and attitudes on unlicensed/off-label paediatric prescribing and paediatric clinical trials. Eur J Clin Pharmacol 67:449-461
20. Olski T, Lampus SF, Gherarducci G, Saint-Raymond A (2011) Three years of paediatric regulation in the European Union. Eur J Clin Pharmacol 67:245-252
21. 'T Jong GW, Eland IA, Sturkenboom MC et al (2002) Unlicensed and off-label prescription of drugs to children: a population based cohort study. BMJ 324:1313-1314
22. Turner S, Gill A, Nunn T et al (1996) Use of 'off-label' and unlicensed drugs in paediatric intensive care unit. Lancet 347:549-550
23. Turner S, Nunn AJ, Fielding K, Choonara I (1999) Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: a prospective study. Acta Paediatr 88:965-968
24. United States Food and Drug Administration (2007) Pediatric Research Equity Act (PREA) and Best Pharmaceuticals for Children Act (BPCA). FDA, Silver Spring. http://www.fda.gov/downloads/Drugs/ DevelopmentApprovalProcess/ DevelopmentResources/UCM049870.pdf. Zugegriffen: 15.01.2013
25. Wilson JT (1999) An update on the therapeutic orphan. Pediatrics 104:585-590